Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / PHARMACEUTCL ETF
-
Number of holders
-
44
-
Total 13F shares, excl. options
-
1,560,984
-
Shares change
-
-338,968
-
Total reported value, excl. options
-
$85,560,052
-
Value change
-
-$19,773,375
-
Put/Call ratio
-
0%
-
Number of buys
-
18
-
Number of sells
-
-22
-
Price
-
$54.79
Significant Holders of VANECK ETF TRUST - PHARMACEUTCL ETF (PPH) as of Q4 2018
54 filings reported holding PPH - VANECK ETF TRUST - PHARMACEUTCL ETF as of Q4 2018.
VANECK ETF TRUST - PHARMACEUTCL ETF (PPH) has 44 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1,560,984 shares
.
Largest 10 shareholders include GOLDMAN SACHS GROUP INC (700,012 shares), MEITAV DASH INVESTMENTS LTD (373,194 shares), CLS Investments, LLC (147,000 shares), CITADEL ADVISORS LLC (80,104 shares), BANK OF AMERICA CORP /DE/ (74,073 shares), MORGAN STANLEY (25,897 shares), Cerity Partners LLC (21,075 shares), ROYAL BANK OF CANADA (17,880 shares), LPL Financial LLC (15,002 shares), and OPPENHEIMER & CO INC (13,763 shares).
This table shows the top 44 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.